Latest news

Respiratory Syncytial Virus (RSV) Antibodies

Comparing potential bispecific formats comprising of trastuzumab and a humanized OKT3

Improving In Vivo Research with Recombinant Mouse Antibodies and Isotype Controls

Prevent catastrophic loss of your hybridoma through antibody sequencing

Absolute Biotech Launches to Offer Antibody Reagents, Services and Expertise to Researchers Worldwide

Recombinant Engineered Anti-Norovirus Antibodies

Using Antibody Sequencing to Save a Contaminated Hybridoma for Recombinant Expression

Why Your Hybridoma Should be Sequenced with NGS Instead of PCR

Recombinant Antibodies Against Nipah Virus

Collaborating with the University of Sheffield to Increase Antibody Expression Yields

Absolute Antibody Increases Automation Capabilities and Expands Production Facility

Spotlight On: Z-DNA Antibodies

Engineering ACE2 Fc Fusion Proteins For COVID-19 Prophylaxis

Monkeypox Virus Antibodies for Research and Diagnostics

Absolute Antibody Expands Prometheus™ Antibody Humanization Service to Include Non-Murine Origin Species

PD-1 Fc Silent™ Antibody Improves Anti-Tumor Activity in Mice

Absolute Antibody Licenses Novel Fc Silencing Technology from mAbsolve

Absolute Antibody Wins Made in the North East Award

Dog Antibodies for Research on Comparative Oncology and Infectious Disease

Anti-SARS-CoV-2 Antibodies Bind to the Coronavirus Omicron Variant

Confirmed Pathogen-Free Expression for All Absolute Antibody Products

Recombinant Engineered Antibodies Against Anthrax

Overcoming Obstacles to Antibody Production with Hybridoma Sequencing

Attending the Queen’s Awards Reception at Windsor Castle

See our Services in Action: Recent publications highlighting our recombinant antibody technology

CHXpress™ Transient CHO Expression Service

Multi-Tag Protein 2 (MTP2), An Engineered Fusion Protein with Epitope Tags

Anti-SARS-CoV-2 Antibodies Bind to the Coronavirus Delta Variant

Anti-TIGIT Antibodies and their Fc Dependency

A Year in the Life of Absolute Antibody Employee, Ella